



**LupusAcademy**

Communicate. Educate. Treat.

**12th ANNUAL MEETING OF THE LUPUS ACADEMY**  
**Meeting Book**

**Virtual Pre-meeting  
1st September 2023**

**Hybrid Annual Meeting (Barcelona)  
8–10th September 2023**



# Welcome

## Dear Friends and Colleagues,

We are delighted to welcome you to the 12<sup>th</sup> Annual Meeting of The Lupus Academy,<sup>†</sup> which will provide the latest insights into research and clinical practice developments and enrich your knowledge of lupus to support your clinical practice. This year we return to Barcelona, where we held our inaugural meeting over a decade ago in 2011. Since then, there has been an influx of exciting scientific advances in lupus, steadily increasing the Lupus Academy's educational repository.

The Lupus Academy is committed to the development of high-quality education, focused on providing new and clinically relevant content through in-person and virtual meetings, aspiring to enhance delivery of excellent patient care in support of continuing efforts to improve patient outcomes.

This year's annual meeting will be complemented by the live online broadcast of selected sessions, as well as catch-up meeting platforms following the meeting. The first part of the meeting will take place online on 1st September 2023, with a 2-hour session focusing on the patient-physician collaboration, aimed to effectively modify disease activity, reduce damage and overall disease burden, and improve treatment outcomes. The main hybrid meeting, which takes place from 8–10th September, consists of a varied and interesting scientific programme designed to share state-of-the-art developments in lupus, stimulate interactive discussions, and reinforce networking among scientists, clinicians, students and other individuals involved in the care of lupus patients. In addition to plenary and workshop sessions, participants will have the opportunity to share their experiences in the Poster, Thieves Market and (new) Lupus Around the World sessions.

Developed by a Steering Committee of 12 international experts in lupus, this year's meeting programme strives to provide new ideas to enrich your clinical practice, develop and sustain enthusiasm for collaborative research. We look forward to your participation in-person or virtually at the 12<sup>th</sup> Annual Meeting of the Lupus Academy.

## The Lupus Academy Steering Committee

### Ricard Cervera

Lupus Academy co-Chair (2023)

### Sandra Navarra

Lupus Academy co-Chair (2023)

**Zahir Amoura**

**Eloisa Bonfá**

**Maria Dall'Era**

**Andrea Doria**

**Thomas Dörner**

**Richard Furie**

**David Isenberg**

**Bernardo Pons-Estel**

**Murray Urowitz**

**Ronald van Vollenhoven**

<sup>†</sup>The Lupus Academy is a long-term initiative dedicated to improving patient outcomes in SLE through an interactive educational forum dedicated to sharing best clinical practice through the dissemination and discussion of clinical and basic scientific research about SLE and allied diseases.



To participate in polling questions and to post your questions to the faculty, download the interactive voting app [Join at [slido.com](https://www.slido.com) #678487]

# Meeting Learning Objectives

The Lupus Academy's 12<sup>th</sup> Annual Meeting programme will focus on current key issues in lupus clinical practice and is designed to facilitate improved understanding of these issues and their management through both didactic lectures and shared clinical insights through case study workshops. At the end of the programme delegates should be able to:

- Discuss how patient-physician-nurse collaboration can help reduce illness burden, modify disease and improve treatment outcomes in SLE
- Describe the evidence supporting approved biologics for SLE and which patients to use them in
- Discuss the management of autoimmunity and vaccination, including herpes zoster, and updated immunization guidelines
- Describe the latest (ACR/EULAR) APS classification criteria
- Explain the disruption points in lupus patient pathways
- Discuss global perspectives on the management of lupus
- Describe and share clinical experience of managing paediatric lupus, lupus nephritis, cardiovascular involvement, severe joint involvement, and skin involvement in SLE
- Explain disease modification strategies for the prevention of organ damage in SLE and lupus nephritis
- Consider future therapies for SLE including JAK/STAT inhibitors, CAR T-cell therapy, and new research expectations on pathogenic mechanisms and novel treatment targets in lupus
- Describe approaches to the optimisation of lupus drug trial designs
- Discuss allied autoimmune diseases, including autoimmune encephalitis, interstitial lung disease and systemic capillary leak syndrome

Abstracts of the presentations are published in the official journal of the 12<sup>th</sup> Annual Meeting:

**LUPUS**  
SCIENCE &  
MEDICINE™  
[lupus.bmj.com](http://lupus.bmj.com)

## Continuing Medical Education



The 12<sup>th</sup> Annual Meeting of the Lupus Academy has been planned and implemented in accordance with the accreditation requirements of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Siyemi Learning and the Lupus Academy. Siyemi Learning is accredited by the ACCME to provide continuing medical education for physicians.

Siyemi Learning designates this live activity for a maximum of *15 AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

## Claiming your CME certificate

You will be able to claim your CME certificate from 22 September 2023.

1. Go to [LupusCME.org](https://LupusCME.org)
2. Select 'Meeting CME' on the top bar
3. Sign in with the email address you used to register for the pre-meeting, if it is the first time you are claiming CME credit from Lupus Academy, use the password *Barcelona2023*.
4. Select "12<sup>th</sup> Annual Meeting of the Lupus Academy "
5. Complete the evaluation and claim your CME Certificate of Attendance.

## Disclosures

Speakers' financial disclosures and biographies can be found from Page 14 and on the meeting website. Neither the Lupus Academy planning staff, Julian Ball, Nicole Elzebroek, Eugene Pozniak, nor staff at Siyemi Learning, have any relevant financial relationships with ineligible companies to disclose.



# Contents

<b>Programme .....</b>	<b>8</b>
<b>Biographies .....</b>	<b>14</b>
<b>Notes .....</b>	<b>38</b>

# Programme

## 12<sup>TH</sup> ANNUAL MEETING OF THE LUPUS ACADEMY

**Pre-Meeting:** 1<sup>st</sup> September 2023  
**Hybrid Meeting:** 8-10<sup>th</sup> September 2023

Catch-up Content available Online until 31<sup>st</sup> December 2023  
<http://www.lupus-academy.org/>

### LUPUS ACADEMY 12<sup>TH</sup> ANNUAL MEETING: PRE-MEETING ONLINE SESSION

Friday 1<sup>st</sup> September 2023

#### REDUCING ILLNESS BURDEN, MODIFYING DISEASE AND IMPROVING TREATMENT OUTCOMES: A PATIENT-PHYSICIAN COLLABORATION

CEST (UTC +2 Barcelona) 14:00–16:00 hours

<b>Moderators: Ricard Cervera (Spain) &amp; Sandra Navarra (Philippines)</b>		
<b>14:00</b>	SLE burden of disease: The patient's perspective	<i>Jeanette Andersen (Denmark)</i>
<b>14:20</b>	Challenges in the development of a universal SLE patient charter	<i>Eloisa Bonfá (Brazil)</i>
<b>14:50</b>	Disease modification and prevention of damage	<i>Murray Urowitz (Canada)</i>
<b>15:20</b>	Biologic disease modifying drugs in SLE	<i>Maria Dall'Era (USA)</i>
<b>15:50</b>	<b>Panel Discussion</b>	<i>All</i>
<b>16:00</b>	<b>Pre-Meeting Session Close</b>	



## Friday 8<sup>th</sup> September 2023

### OPENING SESSION (HYBRID)

CEST (UTC +2 Barcelona) 13:30–16:05 hours  
PST (UTC +8 Manila) 19:30 – 22:05 hours  
EDT (UTC -4 New York) 7:30 AM – 10:05 AM

<b>Moderators: Ricard Cervera (Spain) &amp; Sandra Navarra (Philippines)</b>		
<b>13:30</b>	<b>Opening Address</b>	<i>Ricard Cervera (Spain) &amp; Sandra Navarra (Philippines)</i>
	<b>Hot Topic: New Era of Treatments for SLE</b>	
<b>13:35</b>	Approved biologics for SLE: Which to try first and in which patients?	<i>Ricard Cervera (Spain)</i>
	The case for belimumab	<i>Ronald van Vollenhoven (Netherlands)</i>
	The case for anifrolumab	<i>Eric Morand (Australia)</i>
	<b>Panel Discussion</b>	<i>All</i>
<b>Moderators: Ricard Cervera (Spain) &amp; Sandra Navarra (Philippines)</b>		
	<b>Keynotes</b>	
<b>14:55</b>	New (ACR/EULAR) APS classification criteria	<i>Doruk Erkan (USA)</i>
<b>15:30</b>	Disruption points in lupus patient pathways	<i>Laurent Arnaud (France)</i>
<b>16:05</b>	<b>Break</b>	

### PLENARY I: INFECTIONS IN SLE

CEST (UTC +2 Barcelona) 16:40–17:30

<b>Moderators: Ricard Cervera (Spain) &amp; Sandra Navarra (Philippines)</b>		
<b>16:40</b>	Herpes zoster prevalence and recommendations from clinical trial safety data	<i>Richard Furie (USA)</i>
<b>17:05</b>	Updated immunization guidelines	<i>Nancy Agmon-Levin (Israel)</i>
<b>17:30</b>	<b>Session Close</b>	

### LUPUS AROUND THE WORLD\*

CEST (UTC +2 Barcelona) 17:30–18:30

<b>Moderators: Zahir Amoura (France) and Thomas Dörner (Germany)</b>		
<b>17:30</b>	Evaluation of relative telomere length in patients with systemic lupus erythematosus and its association with clinical characteristics and cognition	<i>Anna Carolina Gomes Tavares (Brazil)</i>
<b>17:40</b>	Causes and associated factors with hospitalization in patients with systemic lupus erythematosus: data from Lupus multicentre registry in Argentina	<i>García Lucila (Argentina)</i>
<b>17:50</b>	Juvenile-onset systemic lupus erythematosus: A study at a tertiary medical centre in Abu Dhabi	<i>Khulood Walid Khawaja (UAE)</i>
<b>18:00</b>	Managing SLE among Filipinos during the pandemic: Challenges and opportunities	<i>Peter Paolo Daleon (Philippines)</i>
<b>18:10</b>	The clinical and immunological profile of SLE patients in the hospital of Monastir	<i>Maha Changuel (Tunisia)</i>
<b>18:20</b>	<b>Discussion and Award</b>	
<b>18:30</b>	<b>Session Close Followed by Poster Viewing and Networking Reception</b>	

\*More Lupus Around the World Posters Available in the Poster Area and at [lupus-academy.org](http://lupus-academy.org)  
Lupus Around the World session not part of the accredited CME total.

# Programme

Saturday 9<sup>th</sup> September 2023

## MEET THE EDITOR (BREAKFAST WORKSHOP)

<b>Moderator: Ronald van Vollenhoven (Netherlands)</b>		
<b>08:00</b>	<b>Introduction: What is happening in the world of publishing?</b> Workshop: How do I get my manuscript published—in the best possible journal? Tips for reviewers: Make it work for the authors and yourself	<i>Ronald van Vollenhoven (Netherlands)</i>
<b>08:50</b>	<b>Session Close</b>	

## INTERACTIVE CASE STUDY WORKSHOPS

CEST (UTC +2 Barcelona) 09:00–10:30

<b>Moderator: Murray Urowitz (Canada)</b>		
<b>09:00</b>	Management of paediatric lupus	<i>Elizabeth Ang (Singapore) Joan Calzada-Hernández (Spain)</i>
<b>Moderator: Thomas Dörner (Germany)</b>		
<b>09:00</b>	Management of cardiovascular involvement in SLE	<i>Bernardo Pons-Estel (Argentina) &amp; Gerard Espinosa (Spain)</i>
<b>Moderator: David Isenberg (United Kingdom)</b>		
<b>09:00</b>	Management of lupus nephritis	<i>Onno Teng (Netherlands) &amp; Luis Quintana (Spain)</i>
<b>Moderator: Zahir Amoura (France)</b>		
<b>09:00</b>	Management of musculoskeletal involvement in SLE	<i>Andrea Doria (Italy) &amp; José Gómez-Puerta (Spain)</i>
<b>Moderator: Ronald van Vollenhoven (Netherlands)</b>		
<b>09:00</b>	Management of skin involvement in SLE	<i>Annegret Kuhn (Germany) &amp; Antonio Guilabert Vidal (Spain)</i>
<b>10:30</b>	<b>Break</b>	

## THIEVES' MARKET\*

CEST (UTC +2 Barcelona) 11:00–12:00

<b>Moderators: Zahir Amoura (France) &amp; Richard Furie (USA)</b>		
<b>11:00</b>	Trick or treat? Hematologic involvement in JSLE – active disease or complications?	<i>Adriana Rodrigues Fonseca (Brazil)</i>
<b>11:15</b>	Beyond coagulation	<i>Elena Heras Recuero (Spain)</i>
<b>11:30</b>	Lupus misdiagnosis: How often we do mistakes?	<i>Dmytro Rekalov (Ukraine) - Virtual</i>
<b>11:45</b>	<b>Discussion and Awards</b>	
<b>12:00</b>	<b>Lunch</b>	

\*Thieves' market session not part of the accredited CME total.

## PRIME TIME SESSION: (HYBRID)

CEST (UTC +2 Barcelona) 13:15–15:25 hours

PST (UTC +8 Manila) 19:15 – 21:25 hours

EDT (UTC -4 New York) 7:15 AM – 9:25 AM

## PART I: THE PATIENT AT CENTRE STAGE

<b>Moderators: Sandra Navarra (Philippines) and Eloisa Bonfá (Brazil)</b>		
<b>13:15</b>	The patient's voice	<i>Jeanette Andersen (Denmark)</i>
<b>13:25</b>	The nurse's perspective	<i>Ada Ferenkeh-Koroma (UK)</i>
<b>13:35</b>	ERN-ReCONNET: A model for patient-healthcare provider collaboration	<i>Marta Mosca (Italy) - Virtual</i>
<b>13:55</b>	<b>Panel Discussion</b>	<i>All</i>
<b>14:15</b>	<b>Part I Session Close</b>	

## PART II: TREATMENT OPTIMIZATION AND DISEASE MODIFICATION IN SLE

<b>Moderators: Ricard Cervera (Spain) &amp; Ronald van Vollenhoven (Netherlands)</b>		
<b>14:15</b>	Disease modification in lupus: An introduction	<i>Ronald van Vollenhoven (Netherlands)</i>
<b>14:25</b>	Optimizing steroid-sparing drugs in SLE	<i>Guillermo Ruiz-Irastorza (Spain)</i>
<b>14:45</b>	Disease modification in lupus nephritis	<i>Manuel Praga (Spain)</i>
<b>15:05</b>	<b>Panel Discussion</b>	<i>All</i>
<b>15:25</b>	<b>Prime Time Session Close and Break</b>	

## INTERACTIVE CASE STUDY WORKSHOPS

CEST (UTC +2 Barcelona) 16:00–17:30

<b>Moderator: Murray Urowitz (Canada)</b>		
<b>16:00</b>	Management of paediatric lupus	<i>Elizabeth Ang (Singapore) &amp; Joan Calzada-Hernández (Spain)</i>
<b>Moderator: Thomas Dörner (Germany)</b>		
<b>16:00</b>	Management of cardiovascular involvement in SLE	<i>Bernardo Pons-Estel (Argentina) &amp; Gerard Espinosa (Spain)</i>
<b>Moderator: David Isenberg (United Kingdom)</b>		
<b>16:00</b>	Management of lupus nephritis	<i>Onno Teng (Netherlands) &amp; Luis Quintana (Spain)</i>
<b>Moderator: Zahir Amoura (France)</b>		
<b>16:00</b>	Management of musculoskeletal involvement in SLE	<i>Andrea Doria (Italy) &amp; José Gómez-Puerta (Spain)</i>
<b>Moderator: Ronald van Vollenhoven (Netherlands)</b>		
<b>16:00</b>	Management of skin involvement in SLE	<i>Annegret Kuhn (Germany) &amp; Antonio Guilabert (Spain)</i>
<b>17:30</b>	<b>Session Close</b>	

# Programme

Sunday 10<sup>th</sup> September 2023

## PLENARY II: PIPELINE AND POTENTIAL SLE THERAPIES

CEST (UTC +2 Barcelona) 08:30–10:30

<b>Moderators: Ronald von Vollenhoven (Netherlands) &amp; David Isenberg (UK)</b>		
<b>08:30</b>	JAK/STAT inhibitors	<i>Antonis Fanouriakis (Greece)</i>
<b>08:50</b>	Plasmacytoid dendritic cells as a treatment target	<i>Richard Furie (USA)</i>
<b>09:10</b>	CAR-T: From our cancer experience to other options	<i>Manel Juan (Spain)</i>
<b>09:30</b>	Other targets: Expectations from research on pathogenic mechanisms	<i>Thomas Dörner (Germany)</i>
<b>09:50</b>	Optimising lupus drug trial designs	<i>Eric Morand (Australia) - Virtual</i>
<b>10:10</b>	<b>Panel Discussion</b>	<i>All</i>
<b>10:30</b>	<b>Break</b>	

## POSTER SESSION: PRESENTATIONS\*

CEST (UTC +2 Barcelona) 11:00–12:00

<b>Moderators: Sandra Navarra (Philippines) &amp; Bernardo Pons-Estel (Argentina)</b>		
<b>11:00</b>	IL-16+ is abundantly expressed by kidney-infiltrating myeloid and lymphoid cells in lupus nephritis: a spatially resolved multiplexed approach	<i>Alessandra Ida Celia (Italy)</i>
<b>11:10</b>	Evaluation of relative telomere length in patients with systemic lupus erythematosus and its association with clinical characteristics and cognition	<i>Anna Carolina Faria Moreira Gomes Tavares (Brazil)</i>
<b>11:20</b>	Characterization of plasma-circulating extracellular vesicles from patients with systemic lupus erythematosus	<i>Paula Ximena Losada Vanegas (Colombia)</i>
<b>11:30</b>	Relationship between retinal microvascular impairment and subclinical atherosclerosis in systemic lupus erythematosus	<i>Sara Ferrigno (Italy)</i>
<b>11:40</b>	Autoantibody clusters correlate with lupus phenotype	<i>Ben Mulhearn (UK)</i>
<b>11:50</b>	<b>Discussion and Award</b>	<i>All</i>
<b>12:00</b>	<b>Poster Viewing and Light Lunch</b>	

\*More Posters Available in the Poster Area and at [lupus-academy.org](http://lupus-academy.org)  
Poster session not part of the accredited CME total.

### PLENARY III: AUTOIMMUNE DISEASES BEYOND SLE (HYBRID)

CEST (UTC +2 Barcelona): 13:00–14:30 hours

PST (UTC +8 Manila) 19:00 – 20:30 hours

EDT (UTC -4 New York) 7:00 AM – 8:30 AM

<b>Moderators: Ricard Cervera (Spain) &amp; Bernardo Pons-Estel (Argentina)</b>		
<b>13:00</b>	Autoimmune encephalitis	<i>Eugenia Martinez-Hernandez (Spain)</i>
<b>13:30</b>	Interstitial lung disease	<i>Vanessa Smith (Belgium) - Virtual</i>
<b>14:00</b>	Systemic capillary leak syndrome	<i>Zahir Amoura (France)</i>
<b>14:30</b>	<b>Meeting Close</b>	<i>Ricard Cervera (Spain) &amp; Sandra Navarra (Philippines)</i>

# Biographies



## Nancy Agmon-Levin, MD

Sheba Medical Center and School of Medicine, Tel-Aviv University, Israel

Nancy Agmon-Levin is a Professor of Clinical Immunology and Allergy at the School of Medicine, Tel-Aviv University and Head of the Clinical Immunology Angioedema and Allergy Department at the Sheba Medical Center, a tertiary center with the largest center for autoimmune diseases in Israel. She is a Lead Israeli Consultant for clinical immunology and autoimmune diseases, particularly systemic lupus erythematosus (SLE) and antiphospholipid syndrome.

Professor Agmon-Levin was the President of the Israeli Association for Allergy and Clinical Immunology between 2013 and 2016 and is currently a leading member of the Israel Association of Allergy and Clinical Immunology Board. She is an active participant in different projects alongside lecturing in immunology and allergy at the School of Medicine, and is a member of the European League Against Rheumatism SLE study group.

Professor Agmon-Levin has made a significant contribution to clinical research in her area of expertise, with a long-standing interest in autoimmune diseases, urticaria, management of drug allergy and others. She has published more than 220 peer reviewed manuscripts, is an active member of various advisory boards, and the Primary Investigator for global clinical trials of lupus, hereditary angioedema, autoimmune diseases, asthma, urticaria and allergic diseases.

### Financial Disclosures

Consultant/Advisor:

Consultant/Advisor:  
AstraZeneca; GSK

*All of the relevant financial relationships listed for this individual have been mitigated.*



## Zahir Amoura, MD, MSc

Pitié-Salpêtrière Hospital, Paris, France

Zahir Amoura is Professor of Internal Medicine at the French National Reference Center for Systemic Lupus Erythematosus at Pitié-Salpêtrière Hospital, a role he has held since 2003. In 2009, Professor Amoura became Head of the Department of Internal Medicine in the same institution.

Professor Amoura completed his Paris Hospital Medical Internship in 1988, and obtained a Masters degree in immunopharmacology in 1989. He was subsequently awarded his MD (silver medal) in 1993 and his qualifying certification in internal medicine in 1994. In 1995, Professor Amoura joined the Department of Internal Medicine at Pitié-Salpêtrière Hospital as a Senior Lecturer and Senior Practitioner. Professor Amoura has published over 693 peer-reviewed papers, of which 293 focused on the immunopathological features of lupus.

### Financial Disclosures

Consultant/Advisor:

AstraZeneca; GSK; Kezar;  
Novartis; Otsuka

Research: Amgen; Roche

*All of the relevant financial relationships listed for this individual have been mitigated.*

*Professor Amoura is a member of the Lupus Academy Steering Committee and has been involved in the planning and development of the Lupus Academy's 12<sup>th</sup> Annual Meeting programme and materials.*





**Jeanette Andersen, MSc**  
Lupus Europe, Denmark

Jeanette Andersen has a Masters degree in German and Philosophy from the University of Copenhagen. In 2011 she was diagnosed with systemic lupus erythematosus, which (in combination with a lot of comorbidities) forced her to go into early retirement. Since then she has immersed herself in the role of a volunteer in the area of rheumatology with a special focus on patient engagement in clinical research.

She is the Chair of Lupus Europe, a EUPATI trained patient expert on medicines Research & Development and the leader of the Lupus Europe Patient Advisory Network. She is also a patient representative (or e-PAG) and a Steering Committee Member in ERN ReCONNET as well as a trustee in the Danish Lupus group underneath Gigtforeningen (the Danish Rheumatism Association). She is a EULAR PARE Committee Member and Chair of the subcommittee on Education & Research as well as Leader of the Editorial Board and Edgar Stene Prize working groups. She also sits on the ACTION Council on patient engagement in rheumatology research.

She has developed an exercise programme for lupus patients, that has been endorsed by both ERN and EULAR and at present she is focussing on developing educational materials on better communication between doctors and patients.

**Financial Disclosures**

None



**Elizabeth Ang, MBBS (Hons), MMed, MRCPCH**  
National University Hospital, Singapore

Elizabeth Ang is Senior Consultant, Paediatric Rheumatology in the Khoo Teck Puat – National University Children's Medical Institute and Assistant Professor at the with the Yong Loo Lin School of Medicine, National University of Singapore. She completed her clinical Paediatric Rheumatology Fellowship in Boston Children's Hospital/Harvard School of Medicine. She is also co-Convenor for the Paediatric Special Interest Group in the Asia Pacific League of Associations for Rheumatology (APLAR). In this role, she leads Paediatric Rheumatology webinars for the region, and is part of various collaborative workgroups.

In her free time, she loves flying to surrounding South East Asian countries like Cambodia, Indonesia, Vietnam, etc... to spread her love of Paediatric Rheumatology and to try and understand (and sometimes tackle, alongside the local healthcare professionals) the challenges of caring for children with rheumatic diseases. She considers it her privilege to have made many friends and learnt so much in the process.

**Financial Disclosures**

None

# Biographies



## Laurent Arnaud, MD, PhD

National Reference Center for Autoimmune Diseases, University Hospitals of Strasbourg, France

Laurent Arnaud is a senior staff Rheumatologist and Professor of Rheumatology at Strasbourg University & Academic Hospitals, France. He is also a lead member of the National reference Center for Autoimmune disease of Strasbourg (RESO).

Professor Arnaud's main clinical interests focus on the care of patients with systemic lupus erythematosus. He is leading a research group focusing on innovative strategies to study the epidemiology and therapeutic management of autoimmune diseases, with a particular interest for the use of digital strategies based on big data and artificial intelligence. With his team at RESO, he has published more than 250 papers in the field of autoimmune diseases and given more than 100 lectures at international meetings.

Professor Arnaud is currently the President of the European Lupus Society (SLEuro) and Disease Coordinator for Lupus of the European Reference Network for rare diseases ReCONNET. He is also a full Systemic Lupus Erythematosus International Collaborating Clinics Group group member, and the curator of a twitter account (@Lupusreference) about lupus education, followed by 15,000 people.

### Financial Disclosures

#### Consultant/Advisor:

AbbVie; Alexion; Alpine;  
Amgen; AstraZeneca;  
Biogen; Bristol Myers Squibb;  
Boehringer-Ingelheim; Chugai;  
GSK; Grifols; Janssen; Kezar;  
LFB; Lilly; Medac; Novartis;  
Ono Pharmaceuticals; Pfizer;  
Roche; UCB

All of the relevant financial relationships listed for this individual have been mitigated.



## Eloisa Bonfá, MD, PhD

University of São Paulo Medical School, São Paulo, Brazil

Eloisa Bonfá is Professor of Rheumatology at the University of São Paulo where she has achieved the remarkable distinction of being the first woman to hold the position of Dean at the University of São Paulo Medical School in its 110-year history.

Throughout her career, Professor Bonfá has made noteworthy contributions to the understanding of systemic lupus erythematosus (SLE) and autoimmunity. Her research has focused on various aspects of SLE, including the association of specific autoantibodies, such as anti-ribosomal P antibodies, with psychiatric manifestations of lupus. She was the first to demonstrate, *in vitro*, the arrhythmogenic potential of purified Ro/SSA antibodies. Additionally, she has investigated the association between anti-ribosomal P antibodies and lupus membranous nephritis. She has conducted research on the impact of hydroxychloroquine blood levels on disease flares, the impact of low doses, and the relevance of obesity in relation to drug levels. Professor Bonfá's contributions extend to the field of vaccine immunogenicity and safety in autoimmune disorders. She has published several papers examining the response and safety profiles of vaccines, such as H1N1 and yellow fever vaccines, in individuals with autoimmune conditions. Recently, she has dedicated her efforts to studying the SARS-CoV-2 vaccine's efficacy and safety in a large population of autoimmune rheumatic disease patients. Her work includes publications in high-impact journals, covering topics such as vaccine response, long-term antibody decay, and the need for booster doses.

Graduating from the University of São Paulo Medical School, Professor Bonfá undertook specialist training in Rheumatology in the same University followed by a 4 year rheumatology research fellowship at the Hospital for Special Surgery, New York, USA, under the supervision of Professor Keith Elkon. She has published more than 400 original papers indexed in PubMed and several book chapters.

*Professor Bonfá is a member of the Lupus Academy Steering Committee and has been involved in the planning and development of the Lupus Academy's 12<sup>th</sup> Annual Meeting programme and materials.*

### Financial Disclosures

None





**Joan Calzada-Hernández, MD**  
Hospital Sant Joan de Déu, Barcelona, Catalonia, Spain

Joan Calzada-Hernández is a Paediatric Rheumatologist at Hospital Sant Joan de Déu, with special interest in lupus and other systemic autoimmune diseases and vasculitis. He is also a teaching collaborator in the Paediatric Rheumatology Fellowship at University of Barcelona. Hospital Sant Joan de Déu Pediatric Rheumatology Department is part of the ERN-RITA network, and is nationally accredited as a reference center of the National Health Service for the treatment of autoinflammatory diseases and systemic autoimmune diseases (CSUR [Spain] and XUEC [Catalonia]).

Dr Calzada-Hernández also has a specific interest in how to apply technological solutions to improve clinical care in rheumatic diseases in children and collaborates with the IT department of Hospital Sant Joan de Déu to develop new electronic medical record-based solutions.

A father of two beautiful girls, he loves spending time with his family and friends. His favourite painter is Joaquín Sorolla, 'master of light'.

**Financial Disclosures**

None



**Professor Ricard Cervera, MD, PhD, FRCP**  
Hospital Clínic of Barcelona, Catalonia, Spain

Ricard Cervera is co-Founder and Head of the Department of Autoimmune Diseases at Hospital Clínic of Barcelona. He is also leader of the Research Group on Systemic Autoimmune Diseases at the Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS) and Professor at the University of Barcelona, where he coordinates the Masters Course on Autoimmune Diseases, and serves as Vice Dean of Academic Affairs and International Relations at its Faculty of Medicine and Health Sciences. Professor Cervera qualified in medicine in 1983 from the University of Barcelona and received his PhD in 1988 for his thesis on anticardiolipin antibodies. He spent 2 years at the Lupus Research Unit at The Rayne Institute, St Thomas' Hospital, London, UK.

Professor Cervera is an Associate Editor of the journals *Lupus Science & Medicine* and *European Journal of Internal Medicine* and is on the Editorial Boards of 20 medical journals. He is a Founding Member of the Board of the European Lupus Society and past-coordinator of the European Working Party on Systemic Lupus Erythematosus (Euro-Lupus Group) (1991–2008) and of the European Forum on Antiphospholipid Antibodies (2009–2017). He is Chairman of the Medical Advisory Board of the Catalan Association of Lupus Patients and Medical Advisor to Lupus Europe. He chaired the 6th, 8th and 11th International Congresses on Autoimmunity, the 1st, 2nd and 5th Latin-American Congresses on Autoimmunity, the 5th Meeting of the European Forum on Antiphospholipid Antibodies and the 8th European Lupus Congress.

Professor Cervera's research interests include clinical and epidemiological aspects of systemic autoimmune diseases, particularly systemic lupus erythematosus and antiphospholipid syndrome, with special focus on its 'catastrophic' variant. He has presented over 1000 invited lectures and published more than 1000 scientific papers (H-Index, 95), including original articles in the *New England Journal of Medicine*, *The Lancet*, *Annals of Rheumatic Diseases*, *Arthritis & Rheumatism*, *American Journal of Medicine* and *Medicine (Baltimore)*. He is co-Editor of 50 books, including 'The Antiphospholipid Syndrome', 'Vascular Manifestations of Systemic Autoimmune Diseases' and 'Diagnostic Criteria in Autoimmune Diseases'.

*Professor Cervera is a member of the Lupus Academy Steering Committee and has been involved in the planning and development of the Lupus Academy's 12<sup>th</sup> Annual Meeting programme and materials.*

**Financial Disclosures**

**Consultant/Advisor:**

AstraZeneca; Celgene; GSK; Janssen; Lilly

*All of the relevant financial relationships listed for this individual have been mitigated.*

# Biographies



## Maria Dall'Era, MD

University of California, San Francisco, USA

Maria Dall'Era is the Jean S. Engleman Distinguished Professor and Chief of the Division of Rheumatology at the University of California, San Francisco (UCSF). She is the Director of the UCSF Lupus Program and the Rheumatology Clinical Research Center. She serves as the Chair of the Lupus Clinical Investigators Network (LuCIN).

Professor Dall'Era earned her medical degree at UCSF, where she also completed her internal medicine residency, serving as Chief Resident, and a fellowship in rheumatology. She is a practicing rheumatologist and clinical researcher who leads an integrated research programme focused on three closely related goals: (i) improving our understanding of the molecular and epidemiologic basis for SLE, (ii) developing novel approaches to the treatment of SLE and lupus nephritis, and (iii) finding biomarkers that predict treatment response and long-term outcome in patients with lupus nephritis. She is currently the Protocol Chair of an NIH-funded clinical trial in lupus nephritis, the Principal Investigator of a CDC-funded longitudinal lupus cohort of patients throughout the San Francisco Bay Area, and an Investigator on various translational studies focused on lupus nephritis and cutaneous lupus. She received the Edmund L. Dubois Memorial Lectureship Award from the American College of Rheumatology and the Ephraim Engleman Award for Excellence in Arthritis Research.

### Financial Disclosures

**Speaker:** AstraZeneca; Aurinia; Biogen; GSK

**Data Monitoring Committee**

**Member:** Gilead; Janssen; Pfizer

*All of the relevant financial relationships listed for this individual have been mitigated.*

*Professor Bonfá is a member of the Lupus Academy Steering Committee and has been involved in the planning and development of the Lupus Academy's 12<sup>th</sup> Annual Meeting programme and materials.*



**Andrea Doria, MD**  
University of Padova, Padova, Italy

Andrea Doria is Professor of Rheumatology and Head of the Rheumatology Unit, Department of Medicine, Padova University School of Medicine, Italy. He is Director of Postgraduate School on Rheumatology of University of Padua. In 2022, the rheumatology unit Professor Doria is leading was appointed EULAR Center of Excellence in Rheumatology 2022-2027

Professor Doria has long-standing experience of the clinical management of patients with systemic lupus erythematosus (SLE) and other connective tissue diseases. The unit which he leads is a tertiary referral rheumatology centre for the diagnosis and management of patients affected with connective tissue diseases and other rare rheumatologic conditions.

He has authored over 500 ISI publications, mostly on SLE. These include clinical studies describing new manifestations or subgroups of autoimmune disorders, prognostic risk factors, diagnostic tests and therapeutic interventions, as well as immunochemical studies that evaluate autoantibodies, epitopes and complementary epitopes of autoantigens.

Professor Doria is incoming President of Italian Society of Rheumatology. In 2016 he founded the European Lupus Society (SLEuro), was the first President of the Executive Committee, and has held the role of SLEuro treasurer since 2017.

Professor Doria was involved as “expert” in the European League Against Rheumatism (EULAR) Standing Committee for the development of clinical and therapeutic recommendations in SLE. He is a member of the Lupus Academy Steering Committee and co-chaired several annual meetings including the 4th held in Rome 27 February to 1 March 2015, the 9th held online 11–13 September 2020, and the 11th held in Florence 8–10 April 2022. He was the Chair of the 10th European Lupus Meeting, held in Venice (Italy) 5–8 October 2016 and the Chair of the 14th International Congress on Systemic Lupus Erythematosus held online 6–9 October 2021. Professor Doria has recently become member of the the Systemic Lupus Erythematosus International Collaborating Clinics (SLICC) group.

**Financial Disclosures**

**Consultant/Advisor:**

*AstraZeneca; GSK; Otsuka*

**Speaker:** *AstraZeneca;*

*Galápagos; GSK; Lilly; Otsuka*

*All of the relevant financial relationships listed for this individual have been mitigated.*

*Professor Doria is a member of the Lupus Academy Steering Committee and has been involved in the planning and development of the Lupus Academy's 12<sup>th</sup> Annual Meeting programme and materials.*

# Biographies



## Thomas Dörner, MD

Charité University Hospitals Berlin, Germany

Thomas Dörner is a board-certified Rheumatologist and Professor of Rheumatology and Hemostaseology at Charité University Hospitals, Berlin, Germany, and group leader at the German Research Center of Rheumatology, Berlin (DRFZ). He qualified in medicine in 1990 at Charité University Hospitals, Berlin, and received his board certification in internal medicine in 1995 before undertaking a postdoctoral fellowship at the University of Texas, Southwestern Medical Center in Dallas, USA, where he researched delineating molecular aspects of B-cell receptor gene usage in autoimmune diseases.

Professor Dörner has received several international and national awards, including the Senior Scholar Award of the American College of Rheumatology, the H Schultze Award of the German League Against Rheumatism, the Randy Fischer Prize for Excellence in flow cytometry, the Schoen Award of the German Society of Rheumatology and the EULAR Honorary award (2023).

Professor Dörner has served as a member of Editorial Boards of leading journals in rheumatology and immunology, including *Arthritis & Rheumatism*, *Arthritis Research & Therapy*, *Annals of the Rheumatic Diseases*, *Global Arthritis Research Network (GARN)*, *Current Reviews in Rheumatology*, the *Brazilian Journal of Rheumatology*, the *European Journal of Immunology*, *Lupus Science & Medicine*, and *Rheumatology Reviews*.

Professor Dörner has led various clinical trials on rheumatic diseases, including systemic lupus erythematosus, Sjogren's syndrome, rheumatoid arthritis, and seronegative spondyloarthropathies. His research interests focus on the characterisation of disturbances of humoral autoimmunity and abnormalities of B cell subsets in the blood versus tissue (lupus, neonatal lupus syndromes, Sjogren's syndrome), exploring innovative therapeutic approaches with particular focus on B-cell directed therapy as well as improving diagnostic tools in autoimmune diseases.

### Financial Disclosures

#### Consultant/Advisor:

AbbVie; AstraZeneca; Bristol Myers Squibb; DFG; GSK; Horizon EU; IQVIA; Janssen; Lilly; MSD; Novartis; Roche/Genentech


#### Research:

AbbVie; AstraZeneca; Bristol Myers Squibb; Janssen; Lilly; MSD; Novartis; Roche/Genentech

*All of the relevant financial relationships listed for this individual have been mitigated.*

*Professor Dörner is a member of the Lupus Academy Steering Committee and has been involved in the planning and development of the Lupus Academy's 12<sup>th</sup> Annual Meeting programme and materials.*





**Doruk Erkan, MD, MPH**  
Hospital for Special Surgery, Weill Cornell Medicine, New York, USA

Doruk Erkan is an adult Rheumatologist and a Clinical Researcher at the Barbara Volcker Center for Women and Rheumatic Diseases, Hospital for Special Surgery, and Professor of Medicine at Weill Cornell Medicine, New York, NY, USA.

In addition to his current antiphospholipid syndrome (APS)-focused clinical practice, Professor Erkan has been involved in APS research since 1997. His APS-related research interest includes identification of factors that increase the risk of thrombosis, thrombosis prevention strategies, new immunomodulatory approaches, microvascular and catastrophic APS, and disease classification. He has been the Principal Investigator in multiple APS clinical trials, received prestigious awards for his research, and has been a member of multiple APS-related national/international committees. He has published approximately 160 APS-related papers, and given circa 200 APS-related invited talks; he has been the co-editor of two APS textbooks and one APS eBook.

Professor Erkan is the founding member and the Executive Committee Co-chair of APS ACTION (Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking) the first ever international multidisciplinary network for APS clinical research and trials ([www.apsacion.org](http://www.apsacion.org)). He was also the organization committee Chair of the 15th International Congress on aPL, which took place in September 2016. More recently, Professor Erkan has been co-Principal Investigator of the ACR/EULAR grant to develop a new APS Classification Criteria.

**Financial Disclosures**

**Consultant/Advisor:** *AbbVie; Chugai*

**Speaker:** *Aurinia; GSK*

**Research:** *GSK; Exagen; Immune Tolerance Network via NIH-NIAID – ACR/EULAR*

*All of the relevant financial relationships listed for this individual have been mitigated.*



**Gerard Espinosa, MD, PhD**  
Hospital Clínic of Barcelona, Catalonia, Spain

Gerard Espinosa is a Consultant at the Department of Autoimmune Diseases, Hospital Clínic of Barcelona, Catalonia, Spain, and Accredited Researcher (R3A) at the Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS). He is also currently Associate Professor of Medicine at the University of Barcelona and Teaching Coordinator at the Clinical Institute of Medicine and Dermatology, Hospital Clinic of Barcelona.

Professor Espinosa obtained his PhD degree in 2003 from the University of Barcelona for his thesis on thrombotic mechanisms in antiphospholipid syndrome and vasculitis. Over the last 20 years, he has investigated systemic autoimmune diseases, focusing on antiphospholipid syndrome and its catastrophic variant, systemic lupus erythematosus and its renal involvement, Behçet's disease, and systemic sclerosis. He is currently the coordinator of the High-Risk Pregnancy clinic for women with autoimmune diseases and the multidisciplinary Lupus Nephritis clinic.

Professor Espinosa has published 342 peer-reviewed papers and 58 book chapters (<https://orcid.org/0000-0003-1336-0163>).

**Financial Disclosures**

**Consultant/Advisor:**

*Lilly; Otsuka*

**Research:** *Boehringer-Ingelheim; GSK; Janssen*

*All of the relevant financial relationships listed for this individual have been mitigated.*

# Biographies



## Antonis Fanouriakis, MD

National and Kapodistrian University of Athens, Greece

Antonis Fanouriakis is an Assistant Professor of Internal Medicine-Rheumatology in the National & Kapodistrian University of Athens (Rheumatology & Clinical Immunology Unit, 4th Department of Internal Medicine, "Attikon" University Hospital, Athens, Greece). His research interests focus on the pathogenesis and treatment of systemic lupus erythematosus, with a particular interest in neuropsychiatric disease. He has participated as fellow in charge of the literature review in the EULAR Task Force for the recommendations for the management of systemic lupus erythematosus, for the 2019 and 2023 updates.

### Financial Disclosures

#### Consultant/Advisor:

AstraZeneca; GSK; Novartis

**Speaker:** AbbVie; Boehringer; Novartis

*All of the relevant financial relationships listed for this individual have been mitigated.*



## Ada Ferenkeh-Koroma, RN, BSc Hons, MSc Rheumatology Nursing

University College Hospital, London, UK

Ada Ferenkeh-Koroma is a Senior Research Nurse and Clinical Nurse specialist in rheumatology. She is also an Employment Coach at The University College London Hospitals (UCLH) NHS Foundation Trust, London, England.

She is a former Outreach Research Sister for Osteoporosis in Camden and Islington (London), with over 27 years of clinical experience in the management of Rheumatology patients.

Ms Ferenkeh-Koroma's clinical and research interests focus on patients with autoimmune rheumatic diseases who suffer from inflammatory arthropathies, lupus and osteoporosis.

She provides Nursing care, knowledge, advice and support, to patients and healthcare providers, in primary and secondary care. She has been actively involved in nursing and clinical research trials within the department of rheumatology at UCLH, which are pursued jointly with the University College London's division of medicine and was study coordinator for the SLICC study at UCLH until study closure. She's a Daisy award nominee and in 2020 was selected as one of the Nurses to commemorate the World Health Organisation's year of the Nurse and midwife at her Hospital Trust, in recognition of her contribution to nursing.

Ms Ferenkeh-Koroma has authored clinical research publications in peer-reviewed journals, including *Arthritis & Rheumatology* and *Nursing Standard*.

### Financial Disclosures

None



**Richard Furie, MD**  
Zucker School of Medicine at Hofstra/Northwell, New York, USA

Richard Furie, Chief of the Division of Rheumatology at Northwell Health, is a rheumatologist whose activities for the last several decades have focused on patient care, physician education, and clinical research in the area of anti-rheumatic drug development. He directs The Program in Novel Therapeutics, the Health System's clinical research programme in musculoskeletal disease. He also directs the Hospital's Systemic Lupus Erythematosus (SLE) and Autoimmune Disease Treatment Center, which has become internationally recognized for its role in the development of new therapies for SLE. Regarded as one of the senior rheumatologists in the New York metropolitan area, he has served as a volunteer for the Arthritis Foundation, the Lupus Foundation of America, the Lupus Research Alliance, and Lupus Therapeutics. For over 20 years he served on many committees of the American College of Rheumatology and was named a Master of the College in 2018. Although often featured as a speaker at national and international conferences, Professor Furie's favourite educational venue is at home with his colleagues and trainees.

**Financial Disclosures**

**Consultant/Advisor:**

AstraZeneca; Biogen;  
Bristol Myers Squibb; GSK;  
Genentech

**Research:** AstraZeneca;  
Biogen; Bristol Myers Squibb;  
Genentech; GSK

All of the relevant financial relationships listed for this individual have been mitigated.

*Professor Furie is a member of the Lupus Academy Steering Committee and has been involved in the planning and development of the Lupus Academy's 12<sup>th</sup> Annual Meeting programme and materials.*



**José A. Gómez-Puerta, MD, PhD, MPH**  
Hospital Clínic of Barcelona, Catalonia, Spain

Jose A. Gómez-Puerta is a specialist in Internal Medicine from the Universidad Pontificia Bolivariana, Medellín, Colombia, and a Rheumatologist at Hospital Clínic of Barcelona, Spain. He was awarded a PhD in Biopathology by the University of Barcelona in 2008. He received further training in the Rheumatology Unit of Guy's Hospital, London, UK, and the Lupus Unit, St. Thomas' Hospital, London, UK, in 1997 and 2001, respectively. He also finished his Masters in Autoimmune Diseases at Universidad de Barcelona and moved for an appointment as Post-Doctoral Research Fellow at Brigham and Women's Hospital at Harvard Medical School, Boston, USA from 2011 to 2014. In 2014, Dr Gómez-Puerta obtained his degree in Master of Public Health at Harvard School of Public Health, Boston, USA.

**Financial Disclosures**

**Consultant/Advisor:**

Galápagos

**Speaker:** Astra Zeneca;  
Galápagos; GSK; Lilly; Pfizer

All of the relevant financial relationships listed for this individual have been mitigated.

Dr Gómez-Puerta's work has focused on the study of autoimmune and immune mediated diseases and he has published around 130 original papers, brief notes or reviews in peer-reviewed journals as well as classification criteria for systemic lupus erythematosus (SLE) and antiphospholipid syndrome and over 200 communications at national and international meetings.

Dr Gómez-Puerta is co-investigator of GLADEL 2.0 study group and member of treat-to-target initiative for SLE. He is a member of the Catalan, Spanish, Colombian and honorary member of Argentinian and Chilean societies of Rheumatology and member of the American College of Rheumatology.

Currently, Dr Gómez-Puerta is the Head of Department of Rheumatology at Hospital Clínic of Barcelona and Associate Professor of Rheumatology at the University of Barcelona, Coordinator of Systemic Autoimmune Diseases Study group of Catalan Society of Rheumatology and member of Executive committee of the European Lupus Society (SLEuro).

# Biographies



**Antonio Guilabert Vidal, MD, PhD**  
Hospital of Granollers, Barcelona, Catalonia, Spain

Antonio Guilabert is the Chief of Department of Dermatology at the University Hospital of Granollers (Barcelona) where he is also responsible for the Unit of Connective Tissue Diseases with Skin Involvement. Since 2016 he has been Professor of Dermatology at the Universitat Internacional de Catalunya.

Dr Guilabert obtained his Medicine Degree in 2001 from the Miguel Hernandez University of Elche (Alicante) and attended the Dermatology Residency Program at Hospital Clínic of Barcelona between 2002 and 2006. He made a research fellowship in immunodermatology with Professor Luis Diaz at the University of North Carolina at Chapel Hill (2009–2010). In 2012 obtained his PhD. with a doctoral thesis on genetic polymorphisms in immune-mediated diseases.

Dr Guilabert's fields of interest are both the study of autoimmune diseases with cutaneous involvement and the pathogenic mechanisms behind blistering diseases and psoriasis. As a result, Dr Guilabert has co-authored more than 50 scientific papers, some of them published in high impact journals as *The Lancet*, *JAMA*, *Trends in Immunology*, *Lupus*, *British Journal of Dermatology*, *JAMA Dermatology* and the *Journal of the American Academy of Dermatology*. He has authored several book chapters on autoimmunity and was speaker in scientific meetings in Spain and in Europe.

## Financial Disclosures

### Consultant/Advisor:

*AbbVie; Amirall*

**Speaker:** *Lilly; Leo Pharma; Sanofi*

*All of the relevant financial relationships listed for this individual have been mitigated.*





**David Isenberg, MD, FRCP, FAMS**  
**University College London, UK**

David Isenberg is Emeritus Professor of Rheumatology at University College London (UCL). He graduated from St. Bartholomew's Hospital, London in 1973, and trained in general medicine, rheumatology, neurology, psychiatry and gastroenterology, becoming a Research Fellow at UCL/The Middlesex Hospital in 1979. He was awarded his MD in 1984, based on his studies of myositis. During a year of research at Tufts University, Boston, he became interested in autoantibody structure/function and origin. He was appointed Consultant Rheumatologist in 1984, Professor in 1991 and became the ARC Diamond Jubilee Chair of Rheumatology at UCL in 1996. He has fellowships of both the Royal College of Physicians and the Academy of Medical Sciences.

**Financial Disclosures**

**Consultant/Advisor:**

*Amgen; AstraZeneca; Bayer; Servier*

*All of the relevant financial relationships listed for this individual have been mitigated.*

Professor Isenberg is on the Editorial Boards of five journals, including the *Journal of Rheumatology*. He is past-Chair of the British Isles Lupus Assessment Group, current Chair of the Lupus UK's Research Committee and past-Chair of the Systemic Lupus International Collaborating Clinics group (1998–2003). During the past 20 years, Professor Isenberg has undertaken many roles at the Versus Arthritis charity and was on the Executive Board from 2013 to 2021.

Professor Isenberg is past-President of the British Society for Rheumatology (2004–2006), chaired the Society's Biologics Register Committee for 5 years (2006–2011) and is a co-Founder of The Lupus Academy. Professor Isenberg was the 2010 recipient of the Evelyn V. Hess Prize from the Lupus Foundation of America for his contribution to lupus research and treatment. He has authored over 600 original articles, 300 reviews/chapters and 20 books, many on topics related to lupus.

Professor Isenberg's principal clinical interests are the development of disease activity and damage assessment tools in patients with lupus. His specialist interest is in the autoantibodies associated with systemic lupus erythematosus, Sjogren's syndrome, myositis and antiphospholipid antibody syndrome. In 2016 he became a Master of the American College of Rheumatology and in 2017 received the Rheumeritus award from the Portuguese Society for Rheumatology. His alter ego writes and plays for Lupus Dave and The Davettes, probably rheumatology's top rock group.

*Professor Isenberg is a member of the Lupus Academy Steering Committee and has been involved in the planning and development of the Lupus Academy's 12<sup>th</sup> Annual Meeting programme and materials.*

# Biographies



## **Manel Juan, MD, PhD**

**Hospital Clínic of Barcelona, IDIBAPS (Research Institute) & Hospital Sant Joan de Déu, University of Barcelona, Catalonia, Spain**

Manel Juan is the head of the Service of Immunology (SI) at Hospital Clínic of Barcelona (HCB) for adults and responsible of Immunotherapy Platform at the paediatric Hospital Sant Joan de Déu Scientific (HSJD), and leader in Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) of the group "Immunogenetics and Immunotherapy of Immune and Autoinflammatory Responses". He is and Immunologist, specializing in Cell and Gene Immunotherapy, and Assistant Professor in the School of Medicine at University de Barcelona (UB).

### **Financial Disclosures**

**Speaker:** Milteny Biotec

**Research support:** Gyala

*All of the relevant financial relationships listed for this individual have been mitigated.*

Professor Juan completed its MD and PhD at the University of Barcelona. He finished his residency in immunology at HCB. Between 1996 and 2007 he worked as an Immunologist at Hospital Germans Trias i Pujol and as head of subprocess at BST (Catalonian Blood and Tissue Bank), and Assistant Professor of the Autonomous University of Barcelona (UAB). In 2007, he returned to HCB as a head of section in the SI, becoming Head of SI of HCB and Assistant Professor of UB in 2020.

Professor Juan leads a translation programme focused in cell and gene immunotherapy [mainly in adoptive cell immunotherapy (ACT), and specially in CAR-T production]. In addition to several proposals for vaccination with monocyte-derived dendritic cells and tumor infiltrating lymphocytes (TILs) as ACT, the most relevant products developed under his direction are a CART19 (ARI-0001) and CART-BCMA (ARI-0002) tested in >200 patients, which resulted in several clinicals trials of ARI-0001 for the authorization of use (under the rule of Hospital Exemption) by Spanish drug agency (AEMPS) and is under evaluation by European Medicine Agency (EMA) following PRIME (Priority Medicine) designation. During his >30 years as an immunologist he has authored over 160 peer-reviewed publications, seven books and received 17 projects as Principal Investigator with over €6 million in peer-reviewed funding, and has been inventor of six patents.



**Annegret Kuhn, MD, MBA, CHCIO**

**Annegret Kuhn, University of Münster, Germany, and Amsterdam Medical Center, The Netherlands**

Annegret Kuhn is Professor (adj.) of Dermatology and Venereology at the University of Münster as well as Research Affiliate and University Lecturer at the School of Business, Economics, and Information Systems at the University of Passau, Germany. She is also Visiting Professor at the Department of Clinical Immunology and Rheumatology at the Amsterdam Medical Center, The Netherlands.

Professor Kuhn obtained her qualifications in Dermatology and Venereology at the University of Duesseldorf, Germany, where she also received her doctorate in medicine and her qualification as a University Lecturer. From 2005 to 2009 she was a Heisenberg-Fellow of the German Research Foundation (DFG) and worked in university departments and scientific institutions such as the Max Planck Institute for Molecular Biomedicine in Muenster and the German Cancer Research Center in Heidelberg, Germany.

Professor Kuhn's main clinical and scientific interest is translational immunology, with a particular interest in the pathogenesis, diagnosis and treatment of cutaneous manifestations in lupus erythematosus. In addition, she has extensive knowledge in all areas of Dermatology and Venereology and has many years of experience in the academic care of inpatients and outpatients with autoimmune diseases. Professor Kuhn chairs national and international guideline committees and works on new diagnostic and therapeutic strategies for cutaneous lupus erythematosus. From 2004 to 2017 she was Chair of the European Society of Cutaneous Lupus Erythematosus (EUSCLE) and is a member of several German and international medical societies and reviewer for several clinical and scientific journals. Professor Kuhn has published widely in high impact journals, including more than 150 original and review articles.

**Financial Disclosures**

**Consultant/Advisor:**

Allmirall-Hermal GmbH; EMD  
Serono/Merck; GSK; Lilly  
Deutschland GmbH

*All of the relevant financial relationships listed for this individual have been mitigated.*

# Biographies



## Eugenia Martinez-Hernandez, MD, PhD

Hospital Clínic of Barcelona, IDIBAPS-Fundació Clínic, University of Barcelona, Spain

Martinez-Hernandez is a Staff Neurologist of the Neuroimmunology Unit and Neurology Department at Hospital Clínic of Barcelona, and Researcher of the group Pathogenesis of autoimmune neuronal diseases at Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)-Fundació Clínic. She is a founding member of the Study group for neurooncology and neuroimmunologic related disorders of the Spanish Society of Neurology. She has wide experience on antibody-associated neurological diseases of the peripheral and central nervous system, with special focus on translational research. In 2014 she was awarded with the Doctoral Extraordinary prize of the Autonomous University of Barcelona for her thesis on diagnostic and prognostic biomarkers in myasthenia gravis. She was a research fellow at the University of Pennsylvania, Philadelphia, USA, in the laboratory of Professor Josep Dalmau. She currently supervises the training of residents and fellows in neuroimmunology especially in disorders other than multiple sclerosis. She has published more than 80 peer-reviewed papers. Dr Martinez-Hernandez has made outstanding contributions to autoimmune neurology research, including autoimmune encephalitis, paraneoplastic syndromes, and neurologic complications of cancer immunotherapy.

### Financial Disclosures

Consultant/Advisor:

Werfen

*All of the relevant financial relationships listed for this individual have been mitigated.*



## Eric Morand, MBBS (Hons), FRACP, PhD

Monash University, Melbourne, Australia

Eric Morand is Dean of the Sub-Faculty of Clinical and Molecular Medicine, at Monash University, and Director of Rheumatology at Monash Health. He graduated from Medicine at Monash University, trained in rheumatology in Australia and at the Royal National Hospital for Rheumatic Diseases, UK and took his PhD at Monash University.

Professor Morand's laboratory research has focussed on glucocorticoid-induced mechanisms in the immune system, with the goal of leveraging natural mechanisms of glucocorticoid action to discover a safe replacement for them. His clinical research focuses on systemic lupus erythematosus, including clinical measurement, outcome predictors, trials, mechanisms, and biomarkers.

Professor Morand's past awards include the Parr Prize of the Australian Rheumatology Association and the Lupus Research Alliance (LRA, US) William E Paul Distinguished Innovator Award. In 2021 he was inducted into the Honour Roll of Monash University, and in 2022 he was awarded the LRA Global Team Science Award, Fellowship of the Australian Academy of Health and Medical Sciences, the Victoria Prize for Science and Innovation, and the Evelyn V. Hess Award of the Lupus Foundation of America.

### Financial Disclosures

Consultant/Advisor: AbbVie;

AstraZeneca; Biogen; Bristol Myers Squibb; EMD Serono; GSK; IGM; Lilly; Novartis; Roche; Zenas

Research: AbbVie; Amgen;

AstraZeneca; Biogen; Bristol Myers Squibb; EMD Serono; GSK; Janssen; Lilly; Roche; UCB

*All of the relevant financial relationships listed for this individual have been mitigated.*





**Marta Mosca, MD, PhD**  
University of Pisa, Italy

Marta Mosca is Professor of Rheumatology at the University of Pisa and Head of the Rheumatology Unit at the Azienda Ospedaliera Universitaria Pisana, Italy. Professor Mosca is also the Director of Fellowship Training Program in Rheumatology at the University of Pisa. Since December 2016 she has been the Coordinator of the European Reference Network on “Rare and Hereditary Connective and Musculoskeletal Diseases” (RECONNET) promoted by the European Commission. She is also the coordinator of the European Commission Program INTEGRATE, which aims at integrating the physician and the patients’ point of view in systemic lupus erythematosus (SLE). Professor Mosca is a member of the Scientific Advisory Board of LUPUS EUROPE.

**Financial Disclosures**

**Consultant/Advisor:**

AbbVie; AstraZeneca; GSK; Idorsia; Lilly; Otsuka; UCB

**Speaker:** AstraZeneca; GSK; Janssen; Lilly

All of the relevant financial relationships listed for this individual have been mitigated.

Professor Mosca has been a member of the Systemic Lupus Erythematosus International Collaborating Clinics Group since November 2019. She has participated in the development of EULAR recommendations for the management of SLE, for women’s health, for the management of antiphospholipid syndrome in adults, and has coordinated the Development of recommendations for monitoring SLE patients in clinical practice and in observational studies. She was a member of the EULAR-ACR steering committee for the development of Classification Criteria for SLE.



**Sandra Navarra, MD**  
University of Santo Tomas, Manila, Philippines

Sandra Navarra is Professor and Head of Rheumatology at University of Santo Tomas Hospital, Manila, Philippines. Professor Navarra is a member of the Lupus Academy Steering Committee, and a founding and executive board member of both Asia Pacific Lupus Collaboration (APLC) and Asian Lupus Nephritis Network (ALNN).

**Financial Disclosures**

**Consultant/Advisor:**

Biogen; Boehringer Ingelheim; Idorsia; Astellas; AstraZeneca; Biogen; Boehringer Ingelheim; Idorsia; GSK; Novartis; Pfizer; Roche

**Speaker:** Astellas; AstraZeneca; Boehringer Ingelheim; GSK; Janssen; Pfizer

**Research:** Aurinia; Horizon Therapeutics; Idorsia; Novartis  
**Data Monitoring Committee:** Biogen


All of the relevant financial relationships listed for this individual have been mitigated.

Professor Navarra is Director of the Lupus Inspired Advocacy (LUISA) Project for lupus education and research, and the People Empowerment for Arthritis and Lupus (PEARL) Movement for lay education and medical assistance programmes, both administered by Rheumatology Educational Trust Foundation Inc. (RETFI) in the Philippines. She served as Secretary General of Asia Pacific League of Associations for Rheumatology (APLAR) and is a former president of Philippine Rheumatology Association (PRA). She currently heads the Special Interest Group (SIG) on systemic lupus erythematosus (SLE) at PRA, and is eminent member of the APLAR SLE-SIG.

Professor Navarra has published widely in the field of lupus and other rheumatic diseases and is the recipient of several university, national and regional awards for her contributions to education and research, including the Philippine College of Physicians Most Distinguished Physician award and the APLAR Master award. She has organised several national and regional educational meetings including the Ten Topics in Rheumatology – Asia (November 2009), first Asian Lupus Summit (November 2012), Asian Lupus Summit by Lupus Academy (March 2014), Lupus Academy (Philippine) Roadshow Meetings (May 2016, November 2017, May 2018, February 2023), Lupus for the Internist (May 2019) and Lupus webinar series (October to December 2020).

*Professor Navarra is a member of the Lupus Academy Steering Committee and has been involved in the planning and development of the Lupus Academy’s 12<sup>th</sup> Annual Meeting programme and materials.*

# Biographies



## **Bernardo Pons-Estel, MD**

**Regional Center for Autoimmune and Rheumatic Diseases and the Cardiovascular Institute of Rosario, Argentina**

Professor Pons-Estel is Head of the Regional Center for Autoimmune and Rheumatic Diseases (CREAR) and the Instituto Cardiovascular de Rosario, Argentina. He received his medical degree from the National University of Rosario. Later he received a Rheumatology Scholarship and went to complete a fellowship at the Division of Rheumatology at the Bellevue Hospital, NYUMC. He completed his training in rheumatology at the University of Missouri, Columbia, and as Assistant Research Professor at the Department of Medicine, Irvington House Institute, NYUMC, USA.

Professor Pons-Estel is the main coordinator for the Latin American Group for the Study of Systemic Lupus Erythematosus (GLADEL), and is co-leader for the Latin American Group for the Study of Rheumatic Diseases in Indigenous People (GLADERPO). He was speaker at more than 275 national and international conferences, and he has more than 160 publications in international indexed journals.

Professor Pons-Estel is the Chair of the Lupus Study Group of PANLAR and member of the Steering Committees of Lupus Academy, Systemic Lupus International Collaborating Clinics (SLICC), and DORIS group.

Professor Pons-Estel was distinguished with the Pan American Spirit award; Master of PANLAR, Master of the American College of Rheumatology (ACR), Master of the Argentine Society of Rheumatology, and more recently as Gold Medal Anibal Ruiz Moreno from PANLAR.

### **Financial Disclosures**


**Consultant/Advisor:** GSK

**Speaker:** GSK

**Research:** Janssen

*All of the relevant financial relationships listed for this individual have been mitigated.*

*Professor Pons-Estel is a member of the Lupus Academy Steering Committee and has been involved in the planning and development of the Lupus Academy's 12<sup>th</sup> Annual Meeting programme and materials.*



## Manuel Praga, MD, PhD

Complutense University and Instituto de Investigación Hospital 12 de Octubre, Madrid, Spain

Manuel Praga is Professor of Medicine at the Complutense University and Investigator at Instituto de Investigación Hospital 12 de Octubre in Madrid, Spain. Professor Praga is a founding member and coordinator of the Group for the Study of Glomerular Diseases of the Spanish Society of Nephrology (GLOSEN). GLOSEN has performed numerous studies on different primary and secondary glomerular diseases published in high-ranking journals and achieving a remarkable impact on clinical practice.

Professor Praga's current research activities focus on primary and secondary glomerular diseases, lupus nephritis, thrombotic microangiopathies and complement-related kidney diseases, diabetic nephropathy and kidney complications of obesity, progression of chronic kidney disease and interstitial nephritis.

Professor Praga has authored more than 400 peer-reviewed publications and numerous book chapters and has received many awards, including the "Iñigo Alvarez de Toledo" award for Clinical Investigation in 2000, 2008, 2011, 2016 and 2021. He has served on the Board of the Spanish Society of Nephrology and is an editorial board member and reviewer for several international journals.

### Financial Disclosures

#### Consultant/Advisor:

Alexion; GSK; Novartis; Otsuka; Sanofi; Travers Therapeutics

#### Speaker:

Alexion; GSK; Novartis; Otsuka; Sanofi; Travers Therapeutics

*All of the relevant financial relationships listed for this individual have been mitigated.*



## Luis Quintana, MD, PhD

Hospital Clínic of Barcelona, Catalonia, Spain

Luis Quintana is the Head of the Clinical Nephrology section in the Nephrology and Renal Transplantation Department at the Hospital Clínic de Barcelona. This section is a member of the European Rare Kidney Disease Reference Network and is endorsed by the national health system as a Reference Center for Complex Glomerular Diseases (CSUR). Professor Quintana is Professor at the Department of Medicine at the University of Barcelona Quintana where he coordinates the subject of kidney diseases in the Master in Autoimmune diseases. He is also a recognized researcher at the Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) and coordinator of the Nephropathology Committee of the Hospital Clínic.

Professor Quintana has given more than 107 invited lectures, published more than 100 scientific articles (h-index: 23), including 45 original studies in journals from the first quartile of his specialty, and three patent applications. He has supervised the training of over 30 fellows in nephrology, internal medicine and rheumatology, especially in glomerular diseases. He has been the director of ten Master's and Bachelor's thesis projects and he currently directs five doctoral thesis projects. He has also co-authored several book chapters on primary and secondary glomerular diseases.

### Financial Disclosures

#### Consultant/Advisor:


Alexion; GSK; Novartis; Otsuka

#### Speaker:

Otsuka

*All of the relevant financial relationships listed for this individual have been mitigated.*

# Biographies



## Financial Disclosures

None

## Guillermo Ruiz-Irastorza, MD, PhD

Autoimmune Research Unit at Cruces University Hospital, Bizkaia, Spain

Guillermo Ruiz-Irastorza received his MD from the Universidad Autónoma de Madrid, Spain in 1990 and became a specialist in Internal Medicine in 1996. Following his PhD from the University of the Basque Country, Spain, in 1999 he spent a year as a Research Fellow at the Lupus Research Unit, St Thomas' Hospital, UK, before returning to the Hospital Universitario Cruces as Consultant Physician in Internal Medicine, where he has lead the Autoimmune Diseases Unit since 2010.

He became Professor of Medicine at the University of the Basque Country, Spain in 2004. He is the coordinator of the Autoimmune, Inflammatory and Infectious Diseases area of Biocruces Bizkaia Health Research Institute, and leads the Autoimmune Diseases Research group.

Professor Ruiz-Irastorza's clinical and research interests focus on systemic lupus erythematosus, antiphospholipid syndrome, and pregnancy and autoimmune diseases. He is author of 237 peer-reviewed publications. His group has contributed to better define the role of antimalarials and different doses of glucocorticoids in the treatment of lupus.

He is a member of the Editorial Board of Lupus, and a reviewer of several journals in the fields of Rheumatology and Autoimmune diseases, including *Annals of Rheumatic Diseases*, *Arthritis & Rheumatology*, *Rheumatology*, *Journal of Rheumatology*, *Lupus Science & Medicine*.



## Financial Disclosures

### Consultant/Advisor:

Boehringer-Ingelheim; Janssen-Cilag

**Speaker:** *Boehringer-Ingelheim; Galápagos; Janssen-Cilag*

**Research:** *Boehringer-Ingelheim; Janssen-Cilag*

All of the relevant financial relationships listed for this individual have been mitigated.

## Vanessa Smith, MD, PhD

Ghent University; Ghent University Hospital; Unit for Molecular Immunology and Inflammation VIB Inflammation Research Centre Ghent, Belgium

Vanessa Smith has been Head of Clinics at the Ghent University Hospital since 2011 and Associate Professor of Rheumatology at the Ghent University since 2014.

Professor Smith is a member of the Steering committee of the European Commission Reference Network on Rare CONnective tissue and complex musculoskeletal diseases NETwork (ERN-ReCONNET) since 2016 and Executive board member of ERN- ReCONNET as coordinator of systemic sclerosis since 2017. She serves as a Belgian national expert contact for Health Authorities and is the Chair of the Flemish network for rare connective tissue diseases.

Professor Smith was awarded the 2011 Belgian Cristina Pivetta prize for "Contribution to treatment strategies and diagnostic algorithms for patients with systemic sclerosis" and received a grant from the Fund for Scientific Research Flanders for her research on capillaroscopy.

Professor Smith currently holds a position as Senior Clinical Investigator of the Research Foundation – Flanders, and is the chair of the EULAR study group on Microcirculation in Rheumatic diseases. She is an organizing/scientific board member of the 2nd up the 11th EULAR courses on capillaroscopy and chairs the EULAR network of training and research, Ghent center for microcirculatory imaging. Since 2020 Prof. Smith is member of the scientific organizing committee of the Systemic Sclerosis World Congresses as well.

At the same time, Professor Smith is co-editor of several books, as well as co-author of book chapters and several manuscripts on SSc/microcirculation (more than 200 publications with a disease-specific H-index of 53).





**Y.K. Onno Teng, MD, PhD**  
Leiden University Medical Center, The Netherlands

Professor Onno Teng is a Nephrology clinician-scientist at the department of Internal Medicine of the Leiden University Medical Center (LUMC) where he leads the national and European recognized center of expertise for Lupus, Vasculitis and Complement-mediated Systemic diseases (LuVaCs). He is Professor of Nephrology in renal autoimmune diseases at the University of Leiden and Chair of the national foundation of Autoimmune Research & Collaboration Hubs (ARCH).


Professor Teng has founded a clinical research program for the development of novel treatment strategies in patients with renal autoimmune diseases including lupus nephritis and ANCA associated vasculitis. Simultaneously, he conducts a translational research program focused on neutrophil extracellular traps, B-cell and plasma cell immunology collectively aimed at innovative immune monitoring of novel treatment strategies for LuVaCs patients.

Professor Teng is actively involved as clinical teacher for Nephrology, Immunology and Basic Physiology & Anatomy in the curriculum of Medicine at Leiden University. He supervises medical students for their scientific as well as clinical internships and clinical bedside teaching of the LUMC Internal Medicine Residents.

**Financial Disclosures**

**Consultant/Advisor:**  
Aurinia; CSL; GSK; Kezar;  
Novartis; Otsuka

*All of the relevant financial relationships listed for this individual have been mitigated.*



**Murray Urowitz, MD**  
University of Toronto, Canada

Murray Urowitz is a Professor Emeritus with the Temerty Faculty of Medicine, University of Toronto. He was the Director of the Centre for Prognosis Studies in the Rheumatic Diseases Toronto Western Hospital from 1995 to 2022 and Director of the Toronto Lupus Program from 1970 to 2022.

Professor Urowitz established the University of Toronto Lupus Clinic and Lupus Databank Research Program in 1970. This extensive longitudinal database is one of the largest such databanks in the world with over 2200 patients. He was Senior Scientist with the Krembil Research Institute and Schroeder Arthritis Institute. Professor Urowitz has published over 469 peer-reviewed papers and 46 book chapters and has supervised the training of over 130 fellows in rheumatology especially in systemic lupus erythematosus.

Professor Urowitz was a founding member of the Systemic Lupus International Collaborating Clinics (SLICC) group and Director of the SLICC Registry for Atherosclerosis. In 1995 he received the Distinguished Rheumatologist Award of the Canadian Rheumatology Association and in 2009 he received the Evelyn V. HESS Award for outstanding contributions to lupus research, awarded by the Lupus Foundation of America. He also received the Queen Elizabeth Diamond Jubilee Medal for longstanding contributions to lupus research work in the field of rheumatology in 2015, and was awarded a Lifetime Achievement Award for commitment to the field of lupus by Lupus Ontario in March 2016. In 2017 he was awarded the Distinguished Clinical Investigator Award for exceptional contributions to the field of rheumatology by the American College of Rheumatology. In May of 2019 he received the University of Toronto Dean's Alumni Lifetime Achievement Award for Global Impact and in 2020 he received the CRA Masters Award for achievements in rheumatology from the Canadian Rheumatology Association.

**Financial Disclosures**

**Consultant/Advisor:**  
AstraZeneca; GSK; Merck;  
Otsuka  
**Speaker:** AstraZeneca; GSK;  
**Research:** GSK;  
**Data Safety Monitoring Committee:** Syneos

*All of the relevant financial relationships listed for this individual have been mitigated.*

*Professor Urowitz is a member of the Lupus Academy Steering Committee and has been involved in the planning and development of the Lupus Academy's 12<sup>th</sup> Annual Meeting programme and materials.*

# Biographies



## Ronald van Vollenhoven, MD, PhD

Amsterdam University Medical Centers, and Amsterdam Rheumatology & Immunology Center, The Netherlands

Professor Ronald van Vollenhoven is Chair of the Department of Rheumatology and Clinical Immunology at the Amsterdam UMC and Director of the Amsterdam Rheumatology Center (ARC) in Amsterdam, the Netherlands.

He received his MD and PhD degrees from the University of Leiden in The Netherlands. After graduating in 1984 he pursued immunology research at Cornell Medical College in New York, followed by residency (specialty training) in Internal Medicine at the State University of New York at Stony Brook, and at Stanford University, USA, leading to an American Board of Internal Medicine certification in both Internal Medicine and Rheumatology.

From 1993 to 1998 Professor van Vollenhoven held a faculty appointment as Assistant Professor of Medicine in the Division of Immunology and Rheumatology at Stanford University, and from 1995 he was the Medical Services Chief and Fellowship Director in that division. In 1998 he moved to Stockholm, Sweden, where he worked as a Senior Physician and Chief of the Clinical Trials Unit in the Department of Rheumatology at the Karolinska University Hospital and Associate Professor of Rheumatology; in 2010, he was appointed as Professor and Chief of the Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID) at the Karolinska Institute.

In January 2016 Professor Vollenhoven was appointed as Professor of Rheumatology at the University of Amsterdam and the VU University, and Chair of Rheumatology at both the AMC and VUMC hospitals, which in 2018 merged into the Department of Rheumatology and Clinical Immunology of the new Amsterdam UMC. He is also the Director of the ARC.

Professor van Vollenhoven's research interests focus around the development and systematic evaluation of biological and immunomodulatory treatments for the rheumatic diseases. With his co-workers, he established the Stockholm registry for biological therapies (the STURE database), which supported research projects relating to clinical efficacy, pharmacology, outcomes and pharmacoeconomics. He has been Principal Investigator in many clinical trials of novel therapies in rheumatic diseases and has contributed to a number of important investigator-initiated trials including the SWEFOT, ADMIRE, and DOSERA trials. He has published over 400 original papers (H-index: 75), book chapters and reviews, and is associate-editor of Dubois' Lupus Erythematosus (Elsevier, 2014), editor of the textbook Clinical Therapy Research in the Inflammatory Diseases (World Scientific Press, 2015), author of the monograph Biological Therapy of Rheumatoid Arthritis (Springer, 2015) and co-author, with Professor Laurent Arnaud, of the Handbook of Systemic Lupus Erythematosus (Springer, 2017). In 2004, Professor van Vollenhoven was awarded the Scandinavian Research Foundation Prize for excellence in clinical research in rheumatology, and he is an honorary member of several rheumatological societies, and in 2019 he was awarded the Dutch Rheumatology Society's highest award, the Jan van Breemen Medal. He is the Editor-in-Chief of Lupus Science & Medicine, Vice-Chair of the EULAR Research Committee, Member of the EULAR, co-founder of the IRBIS registry for biologics in systemic lupus erythematosus (SLE), the CERERRA registries collaboration and the NORD-STAR collaboration for Nordic trials in the rheumatic diseases, and the initiator of the Treat-to-Target-in-SLE and DORIS initiatives.

Professor van Vollenhoven is married and has two grown-up children and in his spare time he plays classical piano.

### Financial Disclosures

#### Consultant/Advisor:

AstraZeneca; Bristol Myers Squibb; GSK; Pfizer; UCB

#### Research:

AbbVie; AstraZeneca; Biogen; Bristol Myers Squibb; Galapagos; GSK; Janssen; Pfizer; UCB

All of the relevant financial relationships listed for this individual have been mitigated.

*Professor van Vollenhoven is a member of the Lupus Academy Steering Committee and has been involved in the planning and development of the Lupus Academy's 12<sup>th</sup> Annual Meeting programme and materials.*



# About the Lupus Academy

## Mission

The Lupus Academy is a not-for-profit, long-term initiative committed to improving patient outcomes in SLE and allied diseases. By providing a highly interactive educational forum, the Lupus Academy is dedicated to sharing best clinical practice through the dissemination and discussion of cutting edge scientific and clinical research.

## Meeting Organisation

The 12<sup>th</sup> Annual Meeting of the Lupus Academy has been developed under the control of the meeting Chairs: Professor Ricard Cervera (Spain) and Professor Sandra Navarra (Philippines), on behalf of the Steering Committee of the Lupus Academy, and with the support of the planning staff at Lupus Academy. It has been developed in Joint Providership with Siyemi Learning, an ACCME-accredited provider for CME compliance and certification. No other individuals or organisations have had any influence over the content of this meeting.

## Other Educational Activities

The Lupus Academy runs an Annual Meeting and several regional Roadshow Meetings each year. It also has an extensive library of presentations that is available to registered members, currently free of charge. The Lupus Academy also provides a series of eLearning activities ([lupuscme.org](http://lupuscme.org)) to support its educational goals. From 2019 Lupus Academy has been proud to be the provider of the eLearning course on SLE for the European League Against Rheumatism (EULAR).

More information about all Lupus Academy educational activities can be found at [lupus-academy.org](http://lupus-academy.org).

## Further Information

The Lupus Academy is a not-for-profit educational foundation with its office in the Netherlands, RSIN 851342097.

Lupus Academy Foundation  
Maasdijk 409  
4264 AS Veen  
The Netherlands

## Supporters



  
Communicate. Educate. Treat.

**Financial Supporters**

**Platinum**  
BMS

**Gold**  
AstraZeneca, GSK

**Silver**  
AbbVie

**Bronze**  
Biogen, Galapagos, Otsuka, UCB

Academy Partner  
Lilly

More supporters are being confirmed

**12<sup>th</sup> Annual Meeting 8-10<sup>th</sup> September 2023 Barcelona**

## In-kind Supporters



Financial and in-kind support is only accepted on a strictly “hands-off” basis, where the supporting companies do not have any control or influence over the planning, content, speaker selection or execution of educational activities. Support is received as educational grants, sponsorship, donations or in-kind, and where used, clearly identified.





































# LupusAcademy

Communicate. Educate. Treat.



Lupus Academy Foundation  
Maasdijk 409  
4264 AS Veen  
The Netherlands

[secretariat@lupus-academy.org](mailto:secretariat@lupus-academy.org)  
+31 416 693 925

Become part of our community:

